Skip to main content

Richard Mural, Michael Liebman, Michael Dunn, Richard Somiari, MaryAnn Guerra, Robert Young, Daniel Von Hoff, Jennifer Gordon, Scott Familant, Shirley Tilghman, and more ...

Premium

Pairings

The Windber Research Institute has made a number of administrative changes, GenomeWeb News has learned. Richard Mural joined the institute as chief scientific officer in September, replacing Michael Liebman, who has become executive director. In the past, Mural was director of scientific content and analysis at Celera Genomics.

Further, Michael Dunn joined Windber as its first chief medical officer in July. He is a retired brigadier general.

Richard Somiari has left his post as chief scientific officer and chief executive officer to found his own company (see below).


MaryAnn Guerra has been promoted to chief operating officer of the Translational Genomics Research Institute of Phoenix, Ariz., TGen said yesterday. Previously, she was TGen's senior vice president of operations. Prior to that, she was executive vice president of the Matthews Media Group. Guerra holds a BA in communications from Ohio State University and an MBA in Science, Innovation, and Technology from George Washington University.


Robert Young has been appointed to the board of directors of Human Genome Sciences, the company said today. He is the president of the Fox Chase Cancer Center in Philadelphia. Young holds an MD from Cornell University Medical College and a BS in zoology from Ohio State University.


Daniel Von Hoff has joined the oncology advisory board of Locus Pharmaceuticals, the Blue Bell, Pa.-based company said yesterday. He is the director of translational research at the Translational Genomics Research Institute in Arizona and a clinical professor of medicine at the University of Arizona.


Jennifer Gordon and Scott Familant have joined the intellectual property group in New York of Sidley Austin Brown & Wood as partners, the company said yesterday. Both have represented pharmaceutical and biotechnology companies, including in actions in the US and abroad to enforce patents on PCR technology. Gordon holds a PhD in life sciences and biochemical engineering from MIT and a JD from Fordham University School of Law. Familant holds a bachelor's degree in chemistry from Cornell University and a JD from George Washington University.


Shirley Tilghman, Princeton University's president and professor of molecular biology, has been appointed to the board of directors of Google. Tilghman was a member of the National Research Council committee that guided the US effort in the Human Genome Project and was a founding member of the National Advisory Council of the Human Genome Project Initiative for the National Institutes of Health. She was also the founding director of Princeton's multi-disciplinary Lewis-Sigler Institute for Integrative Genomics and became the university's president in June 2001.


In conjunction with the recent acquisition of Genaissance Pharmaceuticals by Clinical Data, Kevin Rakin and Joseph "Skip" Klein III have joined the board of directors of Clinical Data, the company said last week. Both were directors of Genaissance.


David Gelfand has retired as vice president of the discovery research division and director of the program in core research of Roche Molecular Systems, GenomeWeb News has learned. He was based at Roche Molecular in Alameda, Calif.

 

New Releases

Beckman Coulter last week launched its Biomek Fly-By barcode reader for sample identification and microplate tracking during processing, the company said. The reader enables the tracking of a sample as it moves through the process, confirming the identification and location and creating a traceable data trail, Beckman added.


Roche Diagnostics launched its LightCycler 480 real-time PCR system this week, the company said. The instrument can be interfaced with robotics, and it provides greater sensitivity and accuracy than the existing LightCycler, the company said.

Filed under

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.